The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).
 
Elena Ioana Braicu
Honoraria - AstraZeneca; GlaxoSmithKline; Merck
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Merck (Inst); Resolve Biosciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - North-East German Society for Gynecological Oncology (NOGGO)
 
Klaus Pietzner
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD; Roche
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; Roche
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Roche
 
Dario Zocholl
No Relationships to Disclose
 
Purificación Estévez-García
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
 
Dionyssios Katsaros
No Relationships to Disclose
 
Toon Van Gorp
Consulting or Advisory Role - AstraZeneca (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Regina Berger
Travel, Accommodations, Expenses - Gilead Sciences
 
Maren Keller
No Relationships to Disclose
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - Alkermes; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro